Boston Therapeutics, Inc. (OTCQB:BTHE)
PharmaceuticalsMassachusetts, United States2-10 Employees
Boston Therapeutics, Inc. is a pharmaceutical manufacturer focused on developing novel therapies and diagnostics aimed at unmet medical needs, with an emphasis on metabolism-related conditions. The company pursues marketing authorization through patents and clinical development to enable worldwide commercialization and application, and operates teams across multiple centers including locations in China. Based in Lawrence, Massachusetts, BTI positions itself as an innovator in metabolic health, targeting major markets such as the US and China where metabolic disorders carry a significant social burden and clinical challenges remain greatest. One of its consumer-facing products, SugarDown, is a chewable dietary supplement designed to reduce the absorption of sugars, carbohydrates, and calories, and is marketed through its associated site. The organization has pursued various research and development activities related to diabetes and metabolic regulation, illustrated by past trials and collaborations, and has reported progress on Phase 2 trials and investigative materials in its public disclosures.
1-888-653-2347 
support@leadiq.com 
